Phase 1/2 study to evaluate the feasibility and tolerability of treatment of previously untreated B-CLL chronic lymphocytic leukemia (B-CLL) patients with recombinant idiotype conjugated to KLH (Id-KLH) [B cell lymphoma vaccine] administered with GM-CSF [granulocyte-macrophage colony-stimulating factors]
Latest Information Update: 03 Nov 2021
At a glance
- Drugs GTOP 99 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genitope Corporation
- 01 Mar 2006 New trial record.